Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PNPT1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PNPT1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PNPT1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PNPT1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PNPT1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005065822 | Thyroid | ATC | RNA transport | 100/6293 | 163/18723 | 3.39e-13 | 1.56e-11 | 100 |
GO:190136124 | Thyroid | ATC | organic cyclic compound catabolic process | 238/6293 | 495/18723 | 1.12e-11 | 4.12e-10 | 238 |
GO:190331324 | Thyroid | ATC | positive regulation of mRNA metabolic process | 75/6293 | 118/18723 | 2.57e-11 | 8.84e-10 | 75 |
GO:001593122 | Thyroid | ATC | nucleobase-containing compound transport | 122/6293 | 222/18723 | 4.30e-11 | 1.41e-09 | 122 |
GO:004873233 | Thyroid | ATC | gland development | 210/6293 | 436/18723 | 1.50e-10 | 4.59e-09 | 210 |
GO:004348725 | Thyroid | ATC | regulation of RNA stability | 97/6293 | 170/18723 | 2.68e-10 | 7.70e-09 | 97 |
GO:006101325 | Thyroid | ATC | regulation of mRNA catabolic process | 95/6293 | 166/18723 | 3.27e-10 | 9.16e-09 | 95 |
GO:004348826 | Thyroid | ATC | regulation of mRNA stability | 90/6293 | 158/18723 | 1.31e-09 | 3.30e-08 | 90 |
GO:000188927 | Thyroid | ATC | liver development | 85/6293 | 147/18723 | 1.37e-09 | 3.43e-08 | 85 |
GO:006100827 | Thyroid | ATC | hepaticobiliary system development | 86/6293 | 150/18723 | 1.96e-09 | 4.78e-08 | 86 |
GO:000756829 | Thyroid | ATC | aging | 166/6293 | 339/18723 | 2.79e-09 | 6.60e-08 | 166 |
GO:004343428 | Thyroid | ATC | response to peptide hormone | 192/6293 | 414/18723 | 3.63e-08 | 6.70e-07 | 192 |
GO:0061157110 | Thyroid | ATC | mRNA destabilization | 52/6293 | 84/18723 | 1.01e-07 | 1.70e-06 | 52 |
GO:0061014110 | Thyroid | ATC | positive regulation of mRNA catabolic process | 53/6293 | 87/18723 | 1.63e-07 | 2.61e-06 | 53 |
GO:0050779110 | Thyroid | ATC | RNA destabilization | 53/6293 | 88/18723 | 2.75e-07 | 4.20e-06 | 53 |
GO:003112312 | Thyroid | ATC | RNA 3'-end processing | 65/6293 | 116/18723 | 5.58e-07 | 7.93e-06 | 65 |
GO:000756924 | Thyroid | ATC | cell aging | 72/6293 | 132/18723 | 5.77e-07 | 8.15e-06 | 72 |
GO:003112413 | Thyroid | ATC | mRNA 3'-end processing | 40/6293 | 62/18723 | 6.25e-07 | 8.65e-06 | 40 |
GO:199054226 | Thyroid | ATC | mitochondrial transmembrane transport | 57/6293 | 102/18723 | 3.05e-06 | 3.49e-05 | 57 |
GO:004346726 | Thyroid | ATC | regulation of generation of precursor metabolites and energy | 68/6293 | 130/18723 | 8.19e-06 | 8.27e-05 | 68 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PNPT1 | SNV | Missense_Mutation | rs765249456 | c.2144G>A | p.Arg715Gln | p.R715Q | Q8TCS8 | protein_coding | deleterious(0.04) | possibly_damaging(0.783) | TCGA-A8-A08J-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
PNPT1 | SNV | Missense_Mutation | | c.675N>C | p.Gln225His | p.Q225H | Q8TCS8 | protein_coding | tolerated(0.14) | benign(0.02) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PNPT1 | SNV | Missense_Mutation | novel | c.16N>G | p.Tyr6Asp | p.Y6D | Q8TCS8 | protein_coding | tolerated_low_confidence(0.2) | benign(0.003) | TCGA-AR-A24H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
PNPT1 | SNV | Missense_Mutation | rs757766273 | c.1148N>T | p.Ser383Leu | p.S383L | Q8TCS8 | protein_coding | deleterious(0) | probably_damaging(0.974) | TCGA-AR-A24S-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | anastrozole | SD |
PNPT1 | SNV | Missense_Mutation | | c.235N>A | p.Ala79Thr | p.A79T | Q8TCS8 | protein_coding | tolerated(0.14) | benign(0.249) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
PNPT1 | SNV | Missense_Mutation | | c.1945N>A | p.Val649Ile | p.V649I | Q8TCS8 | protein_coding | tolerated(0.64) | benign(0.005) | TCGA-BH-A203-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PNPT1 | SNV | Missense_Mutation | rs143022417 | c.839C>T | p.Ser280Leu | p.S280L | Q8TCS8 | protein_coding | tolerated(0.31) | benign(0.005) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PNPT1 | SNV | Missense_Mutation | novel | c.596A>G | p.Glu199Gly | p.E199G | Q8TCS8 | protein_coding | deleterious(0.05) | benign(0.119) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PNPT1 | SNV | Missense_Mutation | novel | c.2036N>C | p.Gly679Ala | p.G679A | Q8TCS8 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-C5-A2LX-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
PNPT1 | SNV | Missense_Mutation | novel | c.1535G>C | p.Gly512Ala | p.G512A | Q8TCS8 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-VS-A9UH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |